LordDragon
@IamLordDragon
Followers
1,110
Following
88
Media
1,117
Statuses
2,128
I know nothing about anything but am willing to learn... :D
Joined February 2020
Don't wanna be here?
Send us removal request.
Explore trending content on Musk Viewer
महात्मा गांधी
• 126161 Tweets
गांधी जयंती
• 117145 Tweets
लाल बहादुर शास्त्री
• 105439 Tweets
からくりサーカス
• 86010 Tweets
ケンタッキー
• 77047 Tweets
#BIFF2024xBILLKIN
• 63711 Tweets
Vance
• 62772 Tweets
ニンテンドーミュージアム
• 61239 Tweets
WONWOO
• 55741 Tweets
リネット
• 49797 Tweets
Walz
• 48583 Tweets
宮崎空港
• 37192 Tweets
原神コラボ
• 29887 Tweets
OFF THE MASK COMING SOON
• 22977 Tweets
青木選手
• 22493 Tweets
MINJI FOR DOOSAN BEARS
• 19613 Tweets
青木の引退試合
• 19486 Tweets
青木さん
• 12929 Tweets
フォーエバーヤング
• 12671 Tweets
Alcaraz
• 12341 Tweets
#しぐれういリアルライブ
• 11552 Tweets
ジャパンダートクラシック
• 11000 Tweets
$AUPH This is wassup 👇🏻🤓🔥🔥
💊 vs 💉 ✅
Faster response ✅
Better response ✅
Stable eGFR beyond 1-yr ✅
Safer profiles than older CNIs ✅
-Less hyperkalemia
-Better lipid profile
-Better blood sugar profile
-Stable Flat-dose/avoid frequent 🩸 draws to monitor adequate dose
0
7
69
A birdie told me that real life experience with
#Lupkynis
thus far are positive 30 days into treatment of LN... patients find it convenient, well tolerated and excellent compliance!
But we all knew that....didn’t we? 😏😉
$AUPH
#LupusNephritis
4
4
70
$AUPH Due to recent “unexpected” developments, LD Equity Research will plan on terminating all future
“Back of The Napkins” model meets TrendLine by LD™️ after this weekend. We apologize for the inconvenience as we move our operations to a beach in the Caribbean with Mojitos.
18
3
63
$AUPH This 👇🏻 IS what we are all waiting for: the foundation to the NEW & IMPROVED SOC! 🥳
Congrats to Aurinia and all the volunteer subjects & LN patients!
#LupusNephritis
#Lupkynis
@Lupus_Chat
@CaringForLupus
@LupusOrg
@LADAOrg
@LupusMalaga
@SENefrologia
@AuriniaPharma
1
12
52
$AUPH These are the most recent graphs of NRx 🥇& TRx 🥇per week according to BBT numbers. 🔥🔥✨
As a reminder, these only serve to give us a 👀 into the overall TREND of Lupkynis longitudinally and not mean to show full data.
Data up to 12-17-21. 🤓
1
6
49
$AUPH Official IPR Termination/Settlement. ✅ 😎 Let’s do this!💪🏻
3
8
50
$AUPH 👀
My “Back Of The Napkin” spreadsheet of Rxs progress…🙃
*Pssst…Psst…Yo Behemoths…crank up the 🔥 bids before it gets more expensive..😉*
(Slaps self…”There’s no damn BO!!”🤨😤)
8
4
49
$AUPH BBT 3-31-23
NRx: TWENTY SIX
TRx: ONE HUNDRED EIGHTY FOUR
End of 1Q23. 😎😉
5
4
47
$AUPH 3 Nephs heading CME sponsored by GSK on LN Tx. No mention of Benny…🤔🧐🤓😬
1
2
46
$AUPH Key Takeaway Points from tonight’s presentation by Dr. Appel:
✅Impressive CRR across all Bx classes, racial/ethnic groups.
✅No significant sustained impact on eGFR (based on P3)
✅A-2 extension study in “couple of months”.
✅Benny’s data only based on IV no SubQ form.
3
9
46
$AUPH As we start seeing coverage pattern being made public by different insurers for
#Lupkynis
, bear in mind that all decisions are based on available clinical evidence. Once AURORA-2 data is available, these may potentially change further....
A review of Classes of LN: 🤓
2
6
42
$AUPH 🐦 🗣: Upwards move in Rx trend. ☝🏻. Continued growth in acceptance and awareness by both main specialties. Real-life experience suggests overall good tolerance with particular enthusiasm with rapid steroids taper. 👌🏻. A Sales force meeting anticipated; topic unknown. 🤓
2
6
43
$AUPH Cequa case terminated. 👏🏻😬
Credit to: steven1x on ST.
0
6
40
$AUPH BBT 2/18/22 🤓
Now we are shakin’ & bakin’….🤜🏻🤛🏻
Let’s be “aggressive” fellas!! 😉👏🏻👏🏻
NRx: 6
TRx: 17
2
5
43
$AUPH 🗣 Clinical Updates for March 2023 on one of the subjects (Subject X) as shared by one of my 🐦.
*Notice this is consistent with PG’s comments on last ER regarding 45% remaining on Lupkynis at 15 months*
Cheers!🙏🏻🤓
2
3
41
$AUPH Birdies are not afraid of Dragons anymore....🤔
Anyways.
12/12 Rxs filled as of 3/12/21.
Area equiv. to 250-300k covered lives. Some pre-auths.
Processed thru their In-house dedicated Rx program.
You won’t see it on usual “terminals”.
Cheers! 🍷😬
10
9
43
$AUPH Top tier medical journal The Lancet with results from -AURORA - May 7, 2021.
🤓 Nice work
@AuriniaPharma
#Lupkynis
#100Lupus
3
9
42
$AUPH 🗣 Clinical Updates for July 2023 on one of the subjects
(Subject N) as shared by one of my 🐦.
*Remains on Lupkynis entering 13th month with continued insurance coverage and no major issues 💪🏻*
Cheers!🙏🏻🤓
0
5
40
$AUPH Just to make it “official” with a PR from the company. 😬. Cheers. 1.1.8. ✊🏻
0
6
39
$AUPH 🗣 Clinical Updates for August 2022 on one of the subjects as shared by one of my 🐦.
1
7
40
$AUPH [NEW] These are the most recent graphs of NRx & TRx per MONTH for FY2021 according to BBT numbers.
As a reminder, these only serve to give us a 👀 into the overall TREND of Lupkynis longitudinally and not mean to show full data.
Data ONLY for 2021. 🤓
0
5
40
$AUPH Jim Simons surely knows wassup…Is his math’ng formulas tell him something..? 🤔 Back to almost the biggest position since 2022…😎 Ma’ man…👊🏻💵💵💵💵
Trivia: His Medallion Fund has only lost money in one single year (1989) net of fees since its inception👏🏻👏🏻
1
2
38
A compendium of today’s legit Behemoths Whisperers…. 🗣
It IS indeed different than prior’s, both on quantity & quality of sources. Let the bidding war begins!
Congrats to all Longs!
Oh, and for those who doubted, constantly bashes & Shorties…I have ✌🏻words: “Good Luck”😉
8
6
38
🐦🗣: Highly respected and renowned KOL expected to give a presentation Lupkynis this next Wednesday.
Stepping it up $AUPH !
A gamechanger in endorsing the next SOC in LN! Bravo! 👌🏻🤓
2
7
39
$AUPH BBT 4/1/22
Atta Boy!! Best Evahhhh!!
THIS IS THE WAY! 👌🏻☝🏻☝🏻👏🏻👏🏻👏🏻💪🏻💪🏻
NRx: 15 🥇
TRx: 26🥇
0
4
37
Random thoughts..... $AUPH
🤓😅🤓🖖
4
7
38
$AUPH 🤓 The consistent outcomes over time reinforce confidence in LUPKYNIS as an important treatment choice for people experiencing the dangerous manifestation of lupus nephritis.
4
4
36
$AUPH Kidney Biopsies Sub-Study from A2 Poster @ Congress of Clinical Rheumatology East Conference 👌🏻🤓
1
2
37
$AUPH BBT 1/14/22 🤓
Good job team Auphie!! 👏🏻👏🏻👏🏻Let’s keep up the good work! 💪🏻💪🏻💪🏻👌🏻😊
NRx: 7
TRx: 12
1
3
38
$AUPH Attendance @ JPM ‘22. 🔥[1/13/22 - Track 3 - 9:45 AM]. 🤓
Credits to: JohnI @ ST.
2
4
36
$AUPH “Biz as usual”. Gotta preach to the masses 🙌🏻🙏🏻
Packages with the latest publication on 3-yrs Safety & Efficacy of VOC in LN from A&R Journal have been distributed this past months to most, if not all, active practicing US Rheumatologists (5k+) & Nephrologists (10k+). 🤓
0
1
38
$AUPH Some of the slides that will be presented at ACR ‘21 in November.
The basis for the new SOC in Tx of LN. 🤓
#LupusNephritis
#Lupkynis
@Lupus_Chat
@CaringForLupus
@LupusOrg
@LADAOrg
@LupusPR
@LupusMalaga
5
3
34
$AUPH The evolution of KDIGO for LN over the past 3 years….🤓
The newly proposed 2023 draft inches closer to mirror the excellent outcomes data observed in the completed AURORA 2 Continuation Study…and an inch closer to SOC…🫶🏻👏🏻👏🏻👏🏻
5
5
36
$AUPH 🗣 Clinical Updates for July 2023 on one of the subjects (Subject X) as shared by one of my 🐦.
*Going strong 💪🏻 on Lupkynis at 16th month with continued insurance coverage and no hiccups*
Cheers!🙏🏻🤓
0
2
37
$AUPH 🗣 Clinical Updates for August 2023 on one of the subjects
(Subject N) as shared by one of my 🐦.
*Remains on Lupkynis past 14th month of continuous insurance coverage without lapses or SAEs 💪🏻*
Cheers!🙏🏻🤓
0
4
36
$AUPH [NEW Dragon Bars 📊]🔥🔥
These are the most recent 📊graphs of NRx & TRx per MONTH according to BBT numbers.
As a reminder, these only serve to give us a 👀 into the overall TREND of Lupkynis longitudinally and not mean to show full data.
Complete data for FY 2021. 🤓
1
4
34
$AUPH 🐦 🗣: “I was told A2 WILL be available this month…soon…”
Place your bets…. 🧨 💣 😬
2
2
35
$AUPH Another 🐦 indicated use of Lupkynis in another patient with Class IV LN this week with swift approval from insurer. May this patient benefit from it!🙏🏻😃
0
1
33
$AUPH 🐦 🗣
✅ Positive real-life response starting to circulate amongst specialists
✅ Slow but increasing opportunities for sales rep to have face-time with docs
✅ Well tolerated overall by patients in real-life reports by physicians
✅ Volume increasing in the past months
2
3
35
$AUPH 🤓 FDA Determination of Regulatory Review of Lupkynis 5-years Patent Extension
0
3
35
$AUPH 🐦🗣: Sweeping product launch and market surveys are being engaged with a large well-regarded market intelligence firm that MAY serve to provide strategic guidance “so biopharma can make decisions with confidence”…..👀😬
1
3
35
$AUPH BBT 12/17/21 🤓
A VERY MERRY Christmas indeed! 💣 💥🔥✨🌟
NRx: 11 🥇
TRx: 20 🥇
1
2
34
$AUPH [Dragon Bar Graphs ™️📊]
These are the most recent NRx/TRx per Quarters according to BBT
#s
. (Note corrections made).
As a reminder, these only serve to give us a 👀 into the overall TREND of Lupkynis longitudinally and not mean to show full data.
Data up to 12-17-21. 🤓
0
2
31
$AUPH 🤓🤓
1
6
33
$AUPH Ronny Gal could be the 🔑 to unlock 🔒 the potential of Lupkynis under the ☂️ of NVS and expand their Immunology focus. 🤓
1
1
34
$AUPH As requested by some that are still interested in BBT
#s
.
These are the most recent graphs of NRx & TRx per Q’s & M’s per BBTs data thus far.
As a reminder, these only serve to give us a 👀 into the overall TREND of Lupkynis longitudinally and not mean to show full data.
1
4
33
$AUPH The Scottish Medicines Consortium approved ✅ Lupkynis+ MMF for treatment active LN 3/4/5+mixed. 🥳🤩😎👏🏻👏🏻🥂
1
5
34
$AUPH 🤓🤯👌🏻
#ACR21
#Abstr1425
Interim AURORA2 (Extension of original RCT to 2 years) showed
#lupus
nephritis patients on voclosporin maintained meaningful low uPCR and stability of eGFR at 2yrs. No unexpected safety signals
@RheumNow
2
2
12
0
4
30
$AUPH 😎👏🏻👏🏻👏🏻
With regard to Strategic Review….”2 parties in that equation…” 😬
1
6
33
$AUPH This 👇🏻 🤩= >1-3yrs Tx. 👌🏻🤓
Renal Biopsy Data Supports Long-Term Voclosporin Use for Lupus Nephritis via
@hcplive
0
1
32
$AUPH These are the most recent graphs of NRx & TRx per week according to BBT numbers.
As a reminder, these only serve to give us a 👀 into the overall TREND of Lupkynis longitudinally and not mean to show full data.
Data up to 4-1-22. 🤓
1
8
31
$AUPH Long Term Phase 3 Data Published in Arthritis & Rheumatology Shows LUPKYNIS® (voclosporin) Preserved Kidney Function Up to Three Years in Lupus Nephritis Patients with No New or Unexpected Adverse Events. 🤓👏🏻👏🏻👏🏻
New
#lupusnephritis
data published in Arthritis & Rheumatology.
#rheumatology
#nephrology
#lupus
#LN
#kidneyhealth
Read more:
0
1
19
2
5
33
1
3
32
$AUPH I was told that another 🐦 has recently initiated use of the best and only available FDA-approved oral therapy for a relapsing LN patient!Prior induction=MMF+Pred.
May this patient benefit from Lupkynis!🙏🏻🤓
0
2
31
$AUPH These are the most recent graphs of NRx & TRx per week according to BBT numbers.
As a reminder, these only serve to give us a 👀 into the overall TREND of Lupkynis longitudinally and not mean to show full data.
Data up to 2-4-22. 🤓
0
5
32
$AUPH Updated 2023 EULAR guidance on Tx for LN with focus on:
✅ 3-yrs using “SOC+”.
✅ Shift to earlier and more frequent use of immunosuppressive Tx.
✅ Early use of combination Tx.
🤓🫶🏻👌🏻
0
2
31
$AUPH The words are catching on....Lupkynis is here to stay as SOC for LN....simple flat-dosing...faster RR...simple oral tx that translate to higher preference and compliance....despite what ICER suggests, it IS the more cost effective option! 💪🏻👍🏻🤓
2
7
31
$AUPH Ready for EULAR 21? 🤓
With this 2-years data, clinicians can confidently harness the power of
#Lupkynis
and offer the best option to treat sufferers of
#LupusNephritis
! 👌🏻🙌🏻
3
6
30
$AUPH Disappointed by guidance? Absolutely. Does it changed my beliefs in the science behind Lupkynis? Nope.
I remain steadfast in my investment.
Everyone needs to manage their own risk tolerance. I know mine’s.
Best of luck ladies & gents.
Cheers!🙏🏻🤓
5
2
31
$AUPH Oppenheimer 33rd Annual Conference most salient data IMO:
2/2 This briefly mentioned data point was not previously available but may indicate an important growth story if sustained…. 💭 🤓😍
1
6
31
$AUPH 👀📈🔥🔥🔥🔥🔥🔥🔥🔥
BBT TRxs #
(Week ending 9/17/21)
NRx #=4 😍
Credits: epausti @ ST
4
1
29
$AUPH Remember that all valuations model thus far have been based on the assumptions of 1-year Induction-Remission Tx. (Pre-AURORA 2 P3 results). Would love to see new models based on 2-3 years use.
Food for thought. 💭 🤔🤓😬
Safety and efficacy of long-term voclosporin treatment for lupus nephritis in the Phase 3 AURORA 2 clinical trial $AUPH
6
7
39
0
4
31
$AUPH Important to combat misinformation and twisted narratives posted by some deranged mind with personal vendetta👇🏻👇🏻🤓
#LupusNephritis
@Lupus_Chat
@CaringForLupus
@LupusOrg
@LADAOrg
@LupusMalaga
@SENefrologia
@AuriniaPharma
1
8
29
$AUPH These are the most recent graphs of NRx & TRx per week according to BBT numbers.
As a reminder, these only serve to give us a 👀 into the overall TREND of Lupkynis longitudinally and not mean to show full data.
Data up to 3-4-22. 🤓
2
4
30
$AUPH 🗣 Clinical Updates for April 2023 on one of the subjects (Subject X) as shared by one of my 🐦.
*Going strong 💪🏻 on Lupkynis at 14th month without any insurance issues reported*
Cheers!🙏🏻🤓
0
4
31
$AUPH 🤔💭
FDA ✅
CHMP ✅
EMA ✅
JAPAN Pending ⭕️
Tutes ⬆️ to 40.9% (ex 13D/G)
2 Founders left w/ options expry EOM
IPR/VOS Settlement ✅
QoQ sales improving ✅
3-years safety data available ✅
First time releasing 4Q + EY Finances ahead of schedule AND before JPM2023 ✅
0
7
29
Take it as it is and whatever it’s worth.... $AUPH
Birdie saysss....
8-9 sales force in this one state.
1 sales person covering 2 cities; has 15 Rxs dispensed....as of 4/9/21
Unknown if the rest has any active Rx’s.
How strong is your math?🤔.
Can you solve this? 🤷🏻♂️😅
12
6
30
$AUPH 🗣 Birdies say: 🐦 Select communities advisory board members will be meeting this Friday & Saturday to discuss diagnosis and tx of LN. 🤓
3
0
28
$AUPH 3Q23: Steady-Eddy 🚂
👏🏻👏🏻👏🏻
✅ Net rev= $40.8M ( ⬆️ 60% 3Q22)
✅ Total net rev thus far 2023=$130.4M➡️tighter lower-bound guidance range to $155-$160M for FY23➡️Notice that they will only need just $29.6M for 4Q23 to meet their upper-bound guidance😉 Easy Peasy. Sneaky PG
2
3
30